Recently, a phase II RCT of Filgotinib (a Jak1-inhibitor) in pSS failed to reach its primary endpoint, consisting of a composite outcome measure; however, a sub-analysis of the trial showed a trend toward clinical efficacy in patients with severe disease [ 91 ].
← all excerpts
Primary-Sjögren's-Syndrome-Related Interstitial Lung Disease: A Clinical Review Discussing Current Controversies.
1
—
—